Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1141 to 1155 of 1877 results for do not dos

  1. Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphoma (TA894)

    Evidence-based recommendations on axicabtagene ciloleucel (Yescarta) for relapsed or refractory follicular lymphoma in adults.

  2. At what gestation should treatment with prophylactic vaginal progesterone for the prevention of preterm birth be started and stopped?

    evidence for the use of progesterone to reduce preterm birth, however studies do not define the optimal gestational age that this...

  3. Glycated haemoglobin testing:- Does optimisation of HbA1c in people with poorly controlled diabetes improve surgical outcomes?

    that doctors often fail to identify high-risk patients before surgery and do not provide perioperative interventions to control HbA1c...

  4. Needle-free arterial non-injectable connector (MIB85)

    NICE has developed a medtech innovation briefing (MIB) on the needle-free arterial non-injectable connector .

  5. URO17 for detecting bladder cancer (MIB250)

    NICE has developed a medtech innovation briefing (MIB) on URO17 for detecting bladder cancer .

  6. Type 2 diabetes: prevention in people at high risk (PH38)

    This guideline covers how to identify adults at high risk of type 2 diabetes. It aims to remind practitioners that age is no barrier to being at high risk of, or developing, the condition. It also aims to help them provide those at high risk with an effective and appropriate intensive lifestyle-change programme to prevent or delay the onset of type 2 diabetes. The recommendations in this guideline can be used alongside the NHS Health Check programme .

  7. Processes and methods for NICE-wide guidance surveillance (PMG49)

    This guide describes the methods and processes that NICE follows to assess the impact of new evidence, changes to the health and care system, or other new, relevant information that has come to light after NICE guidance has published

  8. Percutaneous intradiscal radiofrequency treatment of the intervertebral disc nucleus for low back pain (HTG399)

    Evidence-based recommendations on percutaneous intradiscal radiofrequency treatment of the intervertebral disc nucleus for low back pain. This involves relieving low back pain by delivering heat energy to the damaged disc.

  9. Motivating dental practice teams to take a preventive approach:- What would motivate dental practice teams to take a preventive approach to oral health – especially with high risk groups – and how does this fit into the dental practice business model?

    socioeconomic areas, where patients attend irregularly (or cannot afford to attend) or do not place a high priority on disease...

  10. What interventions are effective to support medicines adherence for people with complex psychosis in supported accommodation?

    medicines in people's recovery, the committee recommended opportunities to do this for those assessed as able to take part. Because of...

  11. Monitoring pulmonary disease:- Is lung clearance index a useful and cost-effective tool for the routine assessment and monitoring of changes in pulmonary status in people with cystic fibrosis?

    disease is difficult in younger children. Not all children under 5 years can do spirometry tests and they are not sufficiently sensitive...

  12. Pegunigalsidase alfa for treating Fabry disease (TA915)

    Evidence-based recommendations on pegunigalsidase alfa (Elfabrio) for Fabry disease (also known as alpha-galactosidase deficiency) in adults.

  13. Pembrolizumab with trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma (TA983)

    Evidence-based recommendations on pembrolizumab (Keytruda) with trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma in adults.

  14. Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer (TA784)

    Evidence-based recommendations on niraparib (Zejula) for treating relapsed, platinum-sensitive high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer in adults.

  15. Avapritinib for treating advanced systemic mastocytosis (TA1012)

    Evidence-based recommendations on avapritinib (Ayvakyt) for treating advanced systemic mastocytosis in adults.